Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of people around the globe and are a major public health burden. Most contemporary …
M Banach, P Burchardt, K Chlebus… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Moreover, over the last few years the approach to treatment of patients with a high cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …
X Bao, Y Liang, H Chang, T Cai, B Feng… - … and Targeted Therapy, 2024 - nature.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …
E Raschi, M Casula, AFG Cicero, A Corsini… - Pharmacology & …, 2023 - Elsevier
The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
Writing Committee, DM Lloyd-Jones, PB Morris… - Journal of the American …, 2022 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg, decision pathways, health policy statements, appropriate use criteria) to provide members …
I Merćep, N Friščić, D Strikić… - Cardiovascular …, 2022 - Wiley Online Library
As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of …
Abstract Inclisiran (Leqvio®; Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates …
C Bardolia, NS Amin, J Turgeon - Frontiers in cardiovascular …, 2021 - frontiersin.org
Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing …
M Ruscica, N Ferri, RD Santos, CR Sirtori… - Current Atherosclerosis …, 2021 - Springer
Purpose of review Based on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin lipid lowering approaches to …